A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adults With DSM-5 Schizophrenia

ClinicalTrials.gov processed this data on November 20, 2023. Link to the current ClinicalTrials.gov record.

Recruitment Status

COMPLETED - HAS RESULTS
 (See Contacts and Locations)
Verified November 2023 by Karuna Therapeutics

Sponsor

Karuna Therapeutics

Information Provided by (Responsible Party)

Karuna Therapeutics

Clinicaltrials.gov Identifier

NCT04659161
Other Study ID Numbers: KAR-007
First Submitted: December 2, 2020
First Posted: December 9, 2020
Results First Posted: December 12, 2023
Last Update Posted: December 12, 2023
Last Verified: November 2023
History of Changes

Listing a study on this site does not mean it has been evaluated by the U.S. Federal Government. The safety and scientific validity of a study listed on ClinicalTrials.gov is the responsibility of the study sponsor and investigators. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.

ClinicalTrials.gov, a resource provided by the U.S. National Library of Medicine (NLM), is a registry and results information database of clinical research studies sponsored or funded by a broad range of public and private organizations around the world. Not all studies listed on ClinicalTrials.gov are funded by the National Institutes of Health (NIH) or other agencies of the U.S. Federal Government. Not all listed studies are regulated and/or reviewed by the U.S. Food and Drug Administration or other governmental entities.

Information on ClinicalTrials.gov is provided by study sponsors and investigators, and they are responsible for ensuring that the studies follow all applicable laws and regulations. NLM staff do not verify the scientific validity or relevance of the submitted information beyond a limited quality control review for apparent errors, deficiencies, or inconsistencies.

Choosing to participate in a study is an important personal decision. Before you participate in a study, discuss all options with your health care provider and other trusted advisors. For more information about participating in clinical studies, see Learn About Clinical Studies, which includes questions that you might want to ask before deciding to participate in a study.

For more information about using the information on ClinicalTrials.gov, please also see Terms and Conditions.

See also the Web Policies and Notices for the NIH web site.

Study Description

Not Provided
Condition or Disease Intervention/Treatment
  • Schizophrenia
  • Schizophrenia; Psychosis
  • Drug: Xanomeline and Trospium Chloride Capsules
  • Drug: Placebo

Study Design

Study TypeInterventional
Actual Enrollment252 participants
Design AllocationRandomized
Interventional ModelParallel Assignment
MaskingTriple
Primary PurposeTreatment
Official TitleA Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adults With DSM-5 Schizophrenia
Study Start DateDecember 16, 2020
Actual Primary Completion DateMay 24, 2022
Actual Study Completion DateMay 24, 2022

Groups and Cohorts

Group/ CohortIntervention/ Treatment
  • KarXT
  • Drug: Xanomeline and Trospium Chloride Capsules
    • Oral xanomeline 50 mg/trospium chloride 20 mg BID (twice a day) for the first 2 days (Days 1 and 2) followed by xanomeline 100 mg/trospium chloride 20 mg BID for the remainder of Week 1 (Days 3 to 7). At Visit 5 (Day 8), dosing was to be titrated upwards to xanomeline 125 mg/trospium chloride 30 mg BID unless the subject was continuing to experience adverse events (AEs) from the previous dose of KarXT 100/20 BID. All subjects who were increased to KarXT 125/30 BID, depending on clinical response and tolerability, had the option to return to KarXT 100/20 BID for the remainder of the treatment period.
  • Placebo
  • Drug: Placebo

    Outcome Measures

    Primary Outcome Measures

    1. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 5 [Baseline and Week 5]
      The PANSS is a medical scale used for measuring symptom severity of participants with schizophrenia. The PANSS rating form contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Participants are rated from 1 to 7 on each symptom scale. It takes approximately 45 to 50 minutes to administer. The total score is the sum of all scales with a minimum score of 30 and a maximum score of 210. A decrease in PANSS total score correlates with an improvement in schizophrenia symptoms.

    Secondary Outcome Measures

    1. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Positive Score at Week 5 [Baseline and Week 5]
      The PANSS is a medical scale used for measuring symptom severity of participants with schizophrenia. The PANSS rating form contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Participants are rated from 1 to 7 on each symptom scale. For positive symptoms in schizophrenia, participants are rated from 1 to 7 on each symptom scale, with a minimum score of 7 and a maximum score of 49. A decrease in PANSS total score correlates with an improvement in schizophrenia symptoms.
    2. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Negative Score at Week 5 [Baseline and Week 5]
      The PANSS rating form contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. For negative symptoms in schizophrenia, participants are rated from 1 to 7 on each symptom scale, with a minimum score of 7 and a maximum score of 49. A decrease in PANSS total score correlates with an improvement in schizophrenia symptoms.
    3. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Marder Factor Negative Score [Baseline and Week 5]
      The Marder Factor Negative Score is derived from the Positive and Negative Syndrome Scale (PANSS) and consists of the sum of 5 negative scales (N) and 2 general scales (G) (N1. Blunted affect; N2. Emotional withdrawal; N3. Poor rapport; N4. Passive/apathetic social withdrawal; N6. Lack of spontaneity; G7. Motor retardation; and G16. Active social avoidance), with a minimum score of 7 and a maximum score of 49. A decrease in PANSS total score correlates with an improvement in schizophrenia symptoms.
    4. Change From Baseline Clinical Global Impression - Severity (CGI-S) Score at Week 5 [Baseline and Week 5]
      The CGI-S modified asked the clinician 1 question: "Considering your total clinical experience, how mentally ill is the participant at this time?" The clinician's answer rated on the following 7-point scale: 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill participants.
    5. Percentage of Positive and Negative Syndrome Scale (PANSS) Responders (>=30% Change in PANSS Total Score) at Week 5 [Baseline and Week 5]
      The PANSS is a medical scale used for measuring symptom severity of participants with schizophrenia. The PANSS rating form contains 7 positive symptom scales, 7 negative system scales, and 16 general psychopathology symptom scales. Participants are rated from 1 to 7 on each symptom scale. The total score is the sum of all scales with a minimum score of 30 and a maximum score of 210. A PANSS responder is defined as a participant with at least a 30% change in PANSS total score compared to baseline at Week 5.

    Eligibility Criteria

    Ages Eligible for Study 18 Years to 65 Years (Adult, Older Adult)
    Sexes Eligible for Study All
    Accepts Healthy Volunteers No
    Inclusion Criteria
    • Subject is aged 18 to 65 years, inclusive, at screening.
    • Subject is capable of providing informed consent.
    • A signed informed consent form must be provided before any study assessments are performed.
    • Subject must be fluent (oral and written) in English to consent
    • Subject has a primary diagnosis of schizophrenia established by a comprehensive psychiatric evaluation based on the DSM-5 criteria and confirmed by Mini International Neuropsychiatric Interview for Schizophrenia and Psychotic Disorder Studies (MINI) version 7.0.2.
    • Subject is experiencing an acute exacerbation or relapse of psychotic symptoms, with onset less than 2 months before screening.
    • The subject requires hospitalization for this acute exacerbation or relapse of psychotic symptoms.
    • If already an inpatient at screening, has been hospitalized for less than 2 weeks for the current exacerbation at the time of screening.
    • Positive and Negative Syndrome Scale total score between 80 and 120, inclusive. Score of ≥4 (moderate or greater) for ≥2 of the following Positive Scale (P) items:
    • Item 1 (P1; delusions)
    • Item 2 (P2; conceptual disorganization)
    • Item 3 (P3; hallucinatory behavior)
    • Item 6 (P6; suspiciousness/persecution)
    • Subjects with no change (improvement) in PANSS total score between screening and baseline (Day -1) of more than 20%.
    • Subject has a CGI-S score of ≥4 at screening and baseline (Day -1) visits.
    • Subject will have been off lithium therapy for at least 2 weeks before baseline and free of all oral antipsychotic medications for at least 5 half-lives or 1 week, whichever is longer, before baseline (Day -1).
    • Subjects taking a long-acting injectable antipsychotic could not have received a dose of medication for at least 12 weeks (24 weeks for INVEGA TRINZA) before baseline visit (Day -1).
    • Subject is willing and able to be confined to an inpatient setting for the study duration, follow instructions, and comply with the protocol requirements.
    • BMI must be ≥18 and ≤40 kg/m2.
    • Subject resides in a stable living situation and is anticipated to return to that same stable living situation after discharge, in the opinion of the investigator.
    • Subject has an identified reliable informant.
    • Women of childbearing potential, or men with sexual partners of childbearing potential, must be able and willing to use at least 1 highly effective method of contraception during the study and for 30 days after the last dose of study drug. Sperm donation is not allowed for 30 days after the final dose of study drug.
    Exclusion Criteria
    • Any primary DSM-5 disorder other than schizophrenia within 12 months before screening (confirmed using MINI version 7.0.2 at screening). Symptoms of mild mood dysphoria or anxiety are allowed as long as these symptoms are not the primary focus of treatment. A screening subject with mild substance abuse disorder within the 12 months before screening must be discussed and agreed upon with the medical monitor before they can be allowed into the study.
    • Subjects who are newly diagnosed or are experiencing their first treated episode of schizophrenia.
    • History or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or oncologic disease or any other condition that, in the opinion of the investigator, would jeopardize the safety of the subject or the validity of the study results.
    • Subjects with HIV, cirrhosis, biliary duct abnormalities, hepatobiliary carcinoma, and/or active hepatic viral infections based on either medical history or liver function test results.
    • History or high risk of urinary retention, gastric retention, or narrow-angle glaucoma.
    • History of irritable bowel syndrome (with or without constipation) or serious constipation requiring treatment within the last 6 months.
    • Risk for suicidal behavior during the study as determined by the investigator's clinical assessment and Columbia-Suicide Severity Rating Scale (C-SSRS).
    • Clinically significant abnormal finding on the physical examination, medical history, ECG, or clinical laboratory results at screening.
    • Subjects cannot currently (within 5 half-lives or 1 week, whichever is longer, before baseline [Day -1]) be receiving oral antipsychotic medications; monoamine oxidase inhibitors; anticonvulsants (eg, lamotrigine, Depakote); tricyclic antidepressants (eg, imipramine, desipramine); selective serotonin reuptake inhibitors; or any other psychoactive medications except for as needed anxiolytics (eg, lorazepam, chloral hydrate).
    • Pregnant, lactating, or less than 3 months postpartum.
    • If, in the opinion of the investigator (and/or Sponsor), subject is unsuitable for enrollment in the study or subject has any finding that, in the view of the investigator (and/or Sponsor), may compromise the safety of the subject or affect his/her ability to adhere to the protocol visit schedule or fulfill visit requirements.
    • Positive test for coronavirus (COVID-19) within 2 weeks before screening and at screening.
    • Subjects with extreme concerns relating to global pandemics, such as COVID-19, that preclude study participation.
    • Subject has had psychiatric hospitalization(s) for more than 30 days (cumulative) during the 90 days before screening.
    • Subject has a history of treatment resistance to schizophrenia medications defined as failure to respond to 2 adequate courses of pharmacotherapy (a minimum of 4 weeks at an adequate dose per the label) or required clozapine within the last 12 months.
    • Subjects with prior exposure to KarXT.
    • Subjects who experienced any adverse effects due to xanomeline or trospium.
    • Participation in another clinical study in which the subject received an experimental or investigational drug agent within 3 months before screening.
    • Risk of violent or destructive behavior.
    • Current involuntary hospitalization or incarceration.

    Contacts and Locations

    Sponsors and Collaborators Karuna Therapeutics
    Locations
    • Woodland International Research Group, LLC | Little Rock, Arkansas, United States, 72211
    • CITrials | Bellflower, California, United States, 90706
    • ProScience Research Institute | Culver City, California, United States, 90230
    • California Clinical Trials Medical Group | Glendale, California, United States, 91206
    • Synergy San Diego | Lemon Grove, California, United States, 91945
    • CNS Network | Long Beach, California, United States, 90806
    • Catalina Research Institute, LLC | Montclair, California, United States, 91763
    • NRC Research Institute | Orange, California, United States, 92868
    • California Neuropsychopharmacology Clinical Research Institute | Pico Rivera, California, United States, 90660
    • California Neuropsychopharmacology Clinical Research Institute | San Diego, California, United States, 92101
    • Schuster Medical Research Institute | Sherman Oaks, California, United States, 91403
    • Innovative Clinical Research, Inc. | Miami Lakes, Florida, United States, 33016
    • Research Centers of America | Oakland Park, Florida, United States, 33334
    • iResearch Atlanta, LLC | Decatur, Georgia, United States, 30030
    • Uptown Research Institute | Chicago, Illinois, United States, 60640
    • Pillar Clinical Research | Lincolnwood, Illinois, United States, 60712
    • Arch Clinical Trials | Saint Louis, Missouri, United States, 63118
    • Altea Research Institute | Las Vegas, Nevada, United States, 89102
    • Hassman Research Institute | Marlton, New Jersey, United States, 08053
    • Neuro-Behavioral Clinical Research | North Canton, Ohio, United States, 44720
    • Community Clinical Research | Austin, Texas, United States, 78754
    • Pillar Clinical Research | Richardson, Texas, United States, 75080
    Investigators

      Study Documents (Full Text)

      More Information

      Additional Relevant MeSH Terms

      • Schizophrenia
      • Schizophrenia Spectrum and Other Psychotic Disorders
      • Mental Disorders